Drug profile · INN
enfortumab vedotin
PADCEV
enfortumab vedotin (PADCEV) is a tubulin inhibitor. Associated with Astellas Pharma Inc.
EMA: approved TGA: approved Antineoplastic and immunomodulating agents (L01) L01FX13
Patents linked 0
Pipeline programs 14
News articles 1
Drug details — enfortumab vedotin
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 14
- Data quality
- 0.83
Quick answer
enfortumab vedotin (PADCEV) is a tubulin inhibitor. Associated with Astellas Pharma Inc.
Key facts
INN enfortumab vedotin
Brand PADCEV
Mechanism Tubulin inhibitor
Target Nectin-4
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01FX13
Originator Astellas Pharma Inc
Mechanism of action
Tubulin inhibitor
Primary target: Nectin-4
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is enfortumab vedotin?
enfortumab vedotin (PADCEV) is a tubulin inhibitor. Associated with Astellas Pharma Inc.
What is the brand name for enfortumab vedotin?
PADCEV is a marketed brand name for enfortumab vedotin. Check FDA Drugs@FDA for the current US label holder and prescribing information.